The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1313
ISSUE1313
June 1, 2009
Metformin/Repaglinide (PrandiMet) for Type 2 Diabetes
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Metformin/Repaglinide (PrandiMet) for Type 2 Diabetes
June 1, 2009 (Issue: 1313)
A new fixed-dose tablet (PrandiMet - Novo Nordisk) combining metformin (Glucophage, and others) and repaglinide (Prandin) has been approved by the FDA for treatment of type 2 diabetes in patients already taking both metformin and repaglinide, or for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.